Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
Intrathecal Trastuzumab for Leptomeningeal Metastases in HER2+ Breast Cancer
This study is currently recruiting participants. Verified January 2014 by Northwestern University Sponsor: Northwestern University Information provided by (Responsible Party): Northwestern University ClinicalTrials.gov Identifier: NCT01325207 First received: March 7, 2011 Last updated: January 13, 2014 Last verified: January 2014 History of Changes
http://clinicaltrials.gov/ct2/html/i...e/triangle.gif Purpose The drug being studied is Trastuzumab, a medicine that is used to slow or stop the growth of cancerous tumors that are HER-2 positive. Patients are being asked to participate in this study because they have been diagnosed with having tumor cells in their spinal fluid. This study will investigate the safety and effects of this drug when given directly into the spinal fluid. Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer The purpose of this research study is to determine a safe dose of the drug Trastuzumab and then determine how effective this treatment is. Study Type: Interventional Study Design: Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment Official Title: Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer http://clinicaltrials.gov/show/NCT01325207 |
All times are GMT -7. The time now is 11:52 PM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021